Article

(2020) Efficacy of melatonin as an adjunct in the treatment of acute mania: A double-blind and placebo-controlled trial. International Clinical Psychopharmacology.

(2019) Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive–compulsive disorder: A double-blind randomized trial with placebo control. Psychiatry and Clinical Neurosciences.

(2019) Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive–compulsive disorder: A double-blind randomized trial with placebo control. Psychiatry and Clinical Neurosciences.

(2019) Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive–compulsive disorder: A double-blind randomized trial with placebo control. Psychiatry and Clinical Neurosciences.

(2017) Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study. Human Psychopharmacology.

(2017) Comparison of saffron and fluvoxamine in the treatment of mild to moderate obsessive-compulsive disorder: A double blind, randomized clinical trial. Iranian Journal of Psychiatry.

(2017) L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Human Psychopharmacology.

(2017) Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. Journal of Psychiatric Research.

(2017) Simvastatin adjunct therapy for negative symptoms of schizophrenia: A randomized double-blind placebo-controlled trial. International Clinical Psychopharmacology.

(2016) Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. Pharmacopsychiatry.

(2015) Celecoxib adjunctive therapy for acute bipolar mania: A randomized, double-blind, placebo-controlled trial. Bipolar Disorders.

(2015) Memantine versus methylphenidate in children and adolescents with attention deficit hyperactivity disorder: A double-blind, randomized clinical trial. Iranian Journal of Psychiatry.

(2015) Sustained-release methylphenidate in methamphetamine dependence treatment: A double-blind and placebo-controlled trial. DARU, Journal of Pharmaceutical Sciences.

(2015) Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences.

(2014) Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial. European Neuropsychopharmacology.

(2014) L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial. Journal of Psychiatric Research.

(2014) Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Psychiatry Research.

(2014) Personality patterns in narcotics anonymous members versus individuals with addiction receiving methadone maintenance therapy. Iranian Journal of Psychiatry.

(2014) Personality patterns in narcotics anonymous members versus individuals with addiction receiving methadone maintenance therapy. Iranian Journal of Psychiatry.

(2014) A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology.

(2013) Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Journal of Psychiatric Research.

(2013) Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: An 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs.

(2013) Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Yandomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology.

(2013) N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled study. Clinical Neuropharmacology.

(2013) A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology.

(2012) A double-blind placebo controlled trial of ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry and Human Development.

(2012) A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology.

(2010) Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: A randomized, double-blind comparison trial. Human Psychopharmacology.

(2010) The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial. Schizophrenia Research.